Solvay

Caught on the wrong foot

24/06/20 -"Solvay’s €1.5bn impairment of the back of the current challenging business situation is the price the current management has to pay for the predecessor’s expensive decisions. The ..."

PDF page sample
Pages
63
Language
English
Published on
24/06/20
Download
You may also be interested by these reports :
13/07/26
Akzo Nobel has rejected another acquisition bid from Nippon. The cited reason for undervaluation is hardly surprising, given that the implied ...
10/07/26
Europe approves genome editing for crop improvement. This means a historical milestone and KWS should structurally benefit mid-term. Add, TP EUR 78 ...
09/07/26
We have reduced our target price, reflecting a combination of lower earnings expectations (detailed below) and a higher multiples-based valuation ...
03/07/26
We have refreshed our peer group to include The Mosaic Company, SABIC Agri Nutrients Company, Nutrien Limited, Fertiglobe and CF Industries. We apply ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO